How much does Bioline Reagents Limited make?

Bioline Reagents Limited reported revenue of £19.8m and £7.6m profit in the year to 31 Dec 2025, according to its accounts filed at Companies House.

How many employees does Bioline Reagents Limited have?

Bioline Reagents Limited reported an average of 37 employees in the year to 31 Dec 2025.

Is Bioline Reagents Limited profitable?

Yes — Bioline Reagents Limited reported a profit of £7.6m in the year to 31 Dec 2025.

Company No. 04838884 · Incorporated 19 Jul 2003

Bioline Reagents Limited

Registered name: BIOLINE REAGENTS LIMITED

Part of Meridian Bioscience, Inc group

Bioline Reagents Limited made £19.8m revenue and £7.6m profit in the year to 31 Dec 2025.

Bioline Reagents Limited’s revenue grew 16% to £19.8m in the year to 31 Dec 2025, with £7.6m profit and 37 employees. The company is classified under “manufacture of other chemical products” and is based in London; we hold 4 years of its filed accounts.

Full P&L filedSection C · ManufacturingSIC 20590Manufacture of other chemical products n.e.c.

Status: Active
Location: London, London
Age: 23 yrs · since 2003
Type: Private Limited Company

Part of a group. The filing indicates this company sits within a group structure, so its results may depend on intra-group trading and it may be hard to replicate independently.

Latest accounts · year to 31 Dec 2025

Key figures

Capital-light

Revenue

£19.8m

Growth ▲16%

Profit

£7.6m

Growth ▲8.4%

Profit margin

38.3%

Gross 76%

Employees

Change ▲2.8%

Profit / employee

£205k

Revenue/employee £535k

Profitable streak

4yrs

Consecutive profitable years in our data

Badges are automated estimates derived from the filed figures — not statements of fact about the company.

4 filed years

Financial history

Multi-year financials, oldest to newest
Year to	30 Sep 2022	31 Dec 2023	31 Dec 2024	31 Dec 2025
Disclosure	Full P&L	Full P&L	Full P&L	Full P&L
Profit & loss
Revenue (turnover)	£63.7m	£21.1m	£17.1m	£19.8m
Cost of sales	£12.5m	£5.2m	£2.7m	£4.7m
Gross profit	£51.2m	£15.9m	£14.4m	£15.1m
Operating profit	£48.6m	£9.7m	£9.5m	£10m
Profit before tax	£48.5m	£9.7m	£9.4m	£10m
Profit after tax	£39.2m	£7.5m	£7m	£7.6m
Profit (best available)	£39.2m	£7.5m	£7m	£7.6m
Staff costs	£2.9m	£3.4m	£2.9m	£2.7m
Employees (average)	43	42	36	37
Ratios
Profit margin	61.5%	35.7%	40.9%	38.3%
Gross margin	80.4%	75.3%	84.4%	76%
Revenue per employee	£1.5m	£502k	£474k	£535k
Profit per employee	£911k	£179k	£194k	£205k
Growth (year on year)
Revenue growth	—	—	—	▲16%
Profit growth	—	—	—	▲8.4%
Headcount growth	—	—	—	▲2.8%
Balance sheet — indirect signals, not revenue
Cash at bank	£13.3m	£3.6m	£2.8m	£1.6m
Net assets	£20.3m	£6.8m	£7.8m	£13.1m
Fixed assets	£550k	£336k	£259k	£779k
Current assets	£22.9m	£9.3m	£9.4m	£13.6m
Debtors	£2.1m	£958k	£2m	£1.7m
Deferred income	£1.3m	£1.2m	£516k	£184k
Source	FullAccounts · bulk data Jul 2024	FullAccounts · bulk data Jul 2024	FullAccounts · bulk data Sep 2025	FullAccounts · bulk data Sep 2026

Derived from the latest filing

How the business works

Profit margin: 38.3%; Profit ÷ revenue.
Gross margin: 76%; Gross profit ÷ revenue. High for software and services.
Revenue per employee: £535k; Revenue ÷ average employees.
Profit per employee: £205k; Profit ÷ average employees.
Cash conversion: —; Cash generated from operations ÷ operating profit. Needs a cash-flow statement.
Fixed assets ÷ revenue: 3.9%; Capital intensity. Low = capital-light, cheaper to start.
Deferred income ÷ revenue: 0.9%; Customers paying upfront (subscriptions, deposits). Approximate when combined with accruals.
Debtors ÷ revenue: 8.6%; Money owed by customers. Low = customers pay quickly.

Indirect — not revenue

Balance-sheet signals

Year-on-year changes in filed balance-sheet items. They can hint at momentum (or investment) but are not revenue or profit and must not be read as such.

Net assets: ▲69%; Now £13.1m
Cash at bank: ▼43%; Now £1.6m
Headcount: ▲3%; Now 37
Deferred income: ▼64%; Now £184k
Fixed assets: ▲200%; Now £779k

Deferred income is reported together with accruals in this filing (“accruals and deferred income”), so it is an approximate signal only.

Corporate ownership

Group structure

Ownership chain

Meridian Bioscience, Inc (registered outside the UK register)ultimate parent75–100%
Meridian Bioscience International Limited75–100%
Bioline Reagents Limitedthis company

Bands show the share of ownership each company holds in the one below it.

Sister companies (1)

Meridian Bioscience UK LimitedFigures not disclosed

From the Persons with Significant Control register (corporate controllers only).

Same industry, similar size

Similar profitable businesses

Industry benchmarks →

Sources

Companies House profile Filing history & original accounts

Latest figures from FullAccounts for the year to 31 Dec 2025 (profit £7.6m), from the Companies House accounts bulk data published Sep 2026. Spotted an error? Request a correction.

Updated from Companies House on 15 Oct 2026

Contains public sector information from Companies House licensed under the Open Government Licence v3.0. Data from Companies House, © Crown copyright. View the licence.